Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well as neurology. BridGene’s pursuit of undruggable targets is enabled ...

Takeda’s (NYSE: TAK) (TSE:4502) plasma-derived therapies (PDT) business, led by Giles Platford, president of Takeda’s Plasma-Derived Therapies Business Unit and chair of the Plasma Protein ...

Thanks to the domestic debut of Paddington in Peru this past weekend, but mostly thanks to the film's outstanding performance in the United Kingdom, the Paddington trilogy has now passed a massive ...

The "Paddington" Cinematic Universe rolls forward with "Paddington in Peru," a kind and cuddly family adventure that nonetheless doesn't measure up to the utterly delightful previous entries in ...

Paddington in Peru takes the Browns on an adventurous journey to find Aunt Lucy. New characters like Madison and Jonathan bring humor and depth to the storyline. Heartfelt moments and a satisfying ...

She’s actually arguably even weirder than Paddington, who despite being an incredibly accident-prone bear, is very normal. While Paddington just wants to make marmalade sandwiches and remind his ...

The trilogy of Paddington movies has been beloved by audiences across the world, with this tender immigrant's story the perfect child-friendly alternative to Brady Corbet's The Brutalist.

With “Paddington in Peru” now on its second week of adventures in U.S. cinemas and having hit a global box office of $125 million, VFX powerhouse Framestore has lifted the lid on how it ...

It might be Valentine's Day, but the only movie you should be watching tonight is Paddington in Peru now that it's available to watch at home. The long-awaited third movie in the beloved series ...

Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker. Weber – who was briefly chief operating officer of Takeda ...

On Monday, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera.